NCT04240106 - Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2023

Conditions

Breast CancerBreast Cancer Metastatic

Interventions

DRUG

Niraparib

Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.

DRUG

Aromatase Inhibitors

Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.

Trial Locations (10)

Centro Oncologico de Galicia, A Coruña

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

Hospital Clinico San Carlos, Madrid

Hospital Universitario 12 de octubre, Madrid

Hospital Universitario Reina Sofía, Córdoba

Hospital Universitario Virgen de la Victoria, Málaga

Instituto Valenciano de Oncología, Valencia

Complejo Asistencial de Ávila, Ávila

Hospital Uniersitario Vall d'Hebron, Barcelona

Hospital Clínic i provincial de Barcelona, Barcelona